A Comparison of Valproate with Carbamazepine for the Treatment of Complex Partial Seizures and Secondarily Generalized Tonic–Clonic Seizures in Adults

New England Journal of Medicine

Volumn 327, Issue 11, 1992, Pages 765-771

  Mattson, Richard H ^a,b   Cramer, Joyce A ^a,b   Collins, Joseph F ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA Cooperative Studies Coordinating Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; VALPROATE SEMISODIUM; VALPROIC ACID;

ABSENCE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG USE; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; HYPERSENSITIVITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEIZURE SUSCEPTIBILITY; SEIZURE THRESHOLD; TONIC CLONIC SEIZURE; VOMITING;

EID: 0026794763     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199209103271104     Document Type: Article

References (34)

1. Hauser WA, Hesdorffer DC. Epilepsy: frequency, causes and consequences. New York: Demos Publications, 1990.
2. Schmidt D. Adverse effects of antiepileptic drugs. New York: Raven Press, 1982.
3. Mattson RH, Cramer JA, Collins JF, VA Epilepsy Cooperative Study Group. Early tolerance to antiepileptic drug side effects: a controlled trial of 247 patients. In: Frey H-H, Fröscher W, Koella WP, Meinardi H, eds. Tolerance to beneficial and adverse effects of antiepileptic drugs. New York: Raven Press, 1986:149–56.
4. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic—clonic seizures. N Engl J Med 1985; 313: 145–51.
5. Mattson RH. Selection of antiepileptic drug therapy. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989:103–15.
6. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. A comparison of phenytoin and valproate in previously untreated adult epileptic patients. J Neurol Neurosurg Psychiatry 1982; 45: 55–9.
7. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985; 48: 639–44.
8. Bourgeois B, Beaumanoir A, Blajev B, et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987; 28: Suppl 2: S8–S11.
9. Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982; 23: 693–720.
10. Mattson RH, Cramer JA. Crossover from polytherapy to monotherapy in primary generalized epilepsy. Am J Med 1988; 84: Suppl 1A: 23–8.
11. Chadwick DW. Valproate monotherapy in the management of generalized and partial seizures. Epilepsia 1987; 28: Suppl 2: S12–S17.
12. Wilder BJ, Ramsay RE, Murphy JV, Karas BJ, Marquardt K, Hammond EJ. Comparison of valproic acid and phenytoin in newly diagnosed tonic—clonic seizures. Neurology 1983; 33: 1474–6.
13. Turnbull DM, Howel D, Rawlins MD, Chadwick DW. Which drug for the adult epileptic patient: phenytoin or valproate? BMJ 1985; 290: 815–9.
14. Hosking G. The pediatric Epiteg trial: a comparative multicenter clinical trial of sodium valproate and carbamazepine in newly diagnosed childhood epilepsy, a preliminary communication. In: Chadwick D, ed. Fourth International Symposium on Sodium Valproate and Epilepsy. London: Royal Society of Medicine Services, 1989:71–80.
15. Fariello R, Smith MC. Valproate: mechanisms of action. In: Levy RH, Mattson RH, Dreifuss FE, Meldrum BS, Penry JK, eds. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989:567–75.
16. Loiseau P, Cohadon S, Jogeix M, Legroux M, Dartigues JF. Efficacité du valproate de sodium dans les épilepsies partielles: étude croissée valproate-carbamazépine. Rev Neurol 1984; 140: 434–7.
17. Dean JC, Penry JK. Carbamazepine/valproate treatment in 100 patients with partial seizures failing carbamazepine monotherapy: long-term follow-up. Epilepsia 1988; 29: 687. abstract.
18. Heller AJ, Chesterman P, Elwes RDC, et al. Monotherapy for newly diagnosed adult epilepsy: a comparative trial and prognostic evaluation. Epilepsia 1989; 30: 648. abstract.
19. Mattson RH, Cramer JA, Delgado Escueta AV, Smith DB, Collins JF. A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults. Neurology 1983; 33: Suppl 1: 14–25.
20. Cramer JA, Smith DB, Mattson RH, Delgado Escueta AV, Collins JF. A method of quantification for the evaluation of antiepileptic drug therapy. Neurology 1983; 33: Suppl 1: 26–37.
21. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981; 22: 489–501.
22. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for classification of epilepsies and epileptic syndromes. Epilepsia 1985; 26: 268–78.
23. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chron Dis 1958; 8: 699–712.
24. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
25. Chadwick D, Turnbull DM. The comparative efficacy of antiepileptic drugs for partial and tonic-clonic seizures. J Neurol Neurosurg Psychiatry 1985; 48: 1073–7.
26. Callaghan N, Kenny RA, O'Neill B, Crowley M, Goggin T. A comparative study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy: a preliminary communication. Br J Clin Pract 1983; 37: Suppl 27: 7–9.
27. Pellock JM, Willmore LJ. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41: 961–4.
28. Loiseau P. Sodium valproate, platelet dysfunction, and bleeding. Epilepsia 1981; 22: 141–6.
29. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med 1988; 84: Suppl 1A: 34–41.
30. Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991; 121: 1421–9.
31. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984; 70: 65–9.
32. Jeavons PM, Clark JE. Sodium valproate in treatment of epilepsy. BMJ 1974; 2: 584–6.
33. Hassan MN, Laljee HCK, Parsonage MJ. Sodium valproate in the treatment of resistant epilepsy. Acta Neurol Scand 1976; 54: 209–18.
34. Price DJE. The advantages of sodium valproate in neurosurgical practice. In: Legg HJ, ed. Clinical and pharmacological aspects of sodium valproate (Epilim) in the treatment of epilepsy. Kent, England: MCS Consultants, 1975:44–9.